Indian generics wave next year set to sink obesity drug price

As several leading Indian drugmakers are readying to launch the generic versions of Danish drug maker Novo Nordisk’s blockbuster weight-loss drug semaglutide in March next year, its price is expected to crash by as much as 80% from the prevailing rate, analysts told ET.

Click here to read full article